The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Management of immune-related adverse events in SCLC
Suresh Senan, MRCP, FRCR, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands, describes management strategies for adverse events related to checkpoint inhibitors in small cell lung cancer (SCLC). Comprehensive support systems for patients undergoing cancer treatment are important, as well as oncology nurses to brief and counsel patients. This approach has been successfully implemented in other cancer types, such as non-small cell lung cancer, and has established a well-established system of clinical support on an outpatient basis. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
